# Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks

> **NCT00540410** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 366 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)
- **DRUG:** Coartem® (arthemether+ lumefantrine)

## Key facts

- **NCT ID:** NCT00540410
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 366 (ACTUAL)
- **Last updated:** 2010-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00540410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00540410, "Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00540410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*